REDWOOD CITY, California, May 5 /PRNewswire/ --
Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced a multi-year agreement with AstraZeneca. AstraZeneca plans to expand the utilization of IPA in its research and target discovery programs to gain deeper domain knowledge of disease-related pathways and targets.
As part of the agreement, AstraZeneca researchers plan to leverage the powerful analysis application, to build biological models, analyze data, and reliably answer sophisticated biological and chemical questions in their effort to identify and progress promising targets.
Results generated in IPA can be easily shared across teams, so researchers can work together to make more informed decisions. IPA is an extensive platform for understanding and communicating the dynamic behaviors of complex biological systems, said Dr Ian Dix, Principal Informatics Scientist, AstraZeneca. IPA can support a wide range of research objectives across our target and biomarker discovery programs - such as providing insight into target efficacy, drugability and, increasingly, toxicity. The richness and contextual nature of the content is important for us because it provides a detailed view of the molecular basis of disease, critical in the drug discovery decision-making process.
We are pleased to enhance and extend our relationship with AstraZeneca and to continue to provide AstraZeneca's researchers with greater workflow and decision support, said Sean Scott, SVP of Sales and Operations at Ingenuity Systems. IPA continues to deliver value to AstraZeneca researchers by providing the right capabilities and content to understand biological systems and uncover insights that impact business decisions.
About Ingenuity Pathways Analysis
Ingenuity Pathways Analysis (IPA) is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals.
About Ingenuity Systems(R)
Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. Our long-term focus on innovation in semantic search has allowed us to create groundbreaking technologies that have one common goal - to generate maximum value from all types of biological and chemical knowledge. Ingenuity offerings leverage the Ingenuity Knowledge Base, which contains uniquely structured literature findings that allow scientists to ask complex biological questions and gain rapid insight into their experimental data or systems of interest. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, academic, and government research institutions worldwide. For more information visit: www.ingenuity.com
AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information visit: www.astrazeneca.com
Heidi Bullock, Director, Marketing of Ingenuity Systems, +1-650-381-5150